Internet non è al passo con i tempi, ma con il futuro

— Anonimo

Reply to comment

The randomised part III APPROPRIATE trial beforehand showed that regorafenib considerably improves survival in sufferers with pre-handled
mCRC and led to regulatory approval.


The content of this field is kept private and will not be shown publicly.